help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-1836
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/4/1261    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sowers, M. R.
Right arrow Articles by Ettinger, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sowers, M. R.
Right arrow Articles by Ettinger, B.
Related Collections
Right arrow Calcium and Bone Metabolism
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 4 1261-1267
Copyright © 2006 by The Endocrine Society

Hormone Predictors of Bone Mineral Density Changes during the Menopausal Transition

MaryFran R. Sowers, Mary Jannausch, Daniel McConnell, Roderick Little, Gail A. Greendale, Joel S. Finkelstein, Robert M. Neer, Janet Johnston and Bruce Ettinger

Departments of Epidemiology and Biostatistics (M.R.S., M.J., D.M., R.L.), School of Public Health, University of Michigan, Ann Arbor, Michigan 48104; Division of Geriatrics (G.A.G.), University of California, Los Angeles, School of Medicine, Los Angeles, California 90095; Endocrine Unit (J.S.F., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114; University of Pittsburgh (J.J.), Pittsburgh, Pennsylvania 15261; and Division of Research (B.E.), Kaiser Permanente Medical Care Program, Oakland, California 94611

Address all correspondence and requests for reprints to: MaryFran Sowers, Ph.D., Department of Epidemiology, School of Public Health, University of Michigan, 339 East Liberty Street, Suite 310, Ann Arbor, Michigan 48104. E-mail: mfsowers{at}umich.edu.

Objective and Context: Our objective was to examine predictability of reproductive hormone concentrations for bone mineral density (BMD) loss during the menopausal transition.

Design: We conducted a longitudinal (five annual examinations), multiple-site (n = 5) cohort study, the Study of Women’s Health Across the Nation (SWAN).

Participants: Participants included, at baseline, 2311 premenopausal or early perimenopausal African-American, Caucasian, Chinese, and Japanese women.

Main Outcome Measures: We assessed annual dual-energy x-ray absorptiometry lumbar spine and total hip BMD measures, with endogenous estradiol (E2), FSH, androgens, and self-reported menstrual bleeding patterns.

Results: Over the 4-yr period, lumbar spine BMD loss was 5.6% in natural postmenopause, 3.9% in surgical postmenopause, or 3.2% in late perimenopause. Baseline FSH concentrations, subsequent FSH levels, and their interaction predicted 4-yr BMD loss. If baseline FSH was less than 25 mIU/ml, higher follow-up FSH (>70 mIU/ml) predicted a 4-yr spine BMD loss of –0.05 g/cm2. If baseline FSH values were more than 35–45 mIU/ml, lower follow-up FSH (i.e. 40–50 mIU/ml) predicted a –0.05 g/cm2 4-yr spine BMD loss. Charts show amounts of predicted BMD losses with combinations of baseline FSH values and FSH levels over time. E2 concentrations less than 35 pg/ml were associated with lower BMD, but annual E2 measures and changes did not predict BMD loss. Testosterone, free androgen index, and dehydroepiandrosterone sulfate concentrations were not significantly associated with BMD loss.

Conclusions: Spine and hip BMD losses during the menopause transition were most strongly related to the interaction between initial FSH levels and longitudinal FSH changes and not to E2 or androgen levels or changes.




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
B. A. CROMER
Menstrual Cycle and Bone Health in Adolescents
Ann. N.Y. Acad. Sci., June 1, 2008; 1135(1): 196 - 203.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
M. ZAIDI, H. C. BLAIR, J. IQBAL, L. L. ZHU, T. R. KUMAR, A. ZALLONE, and L. SUN
Proresorptive Actions of FSH and Bone Loss
Ann. N.Y. Acad. Sci., November 1, 2007; 1116(1): 376 - 382.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Iqbal, L. Sun, T. R. Kumar, H. C. Blair, and M. Zaidi
Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation
PNAS, October 3, 2006; 103(40): 14925 - 14930.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society